Cornerstone Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cornerstone Pharmaceuticals, Inc.
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Rafael’s lead drug candidate has failed in a Phase III trial for pancreatic cancer and the company has been advised to stop a Phase III study of the product in AML.
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Rafael Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.